![](/wp-content/uploads/2020/08/ProventionBioAnnouncement.png)
$599
Teplizumab Approved as Tzield; Sernova Implants First Two Patients in Second Cohort of Ph1/2 T1DM Trial
Two cardiometabolic-related news items have been observed: Provention Bio announced the FDA approval of teplizumab to delay the onset of T1DM; and Sernova announced the first two patients in the second cohort of its Ph1/2 trial in T1DM have been implanted (view CT.gov record). Below, FENIX provides highlights and insights from the respective news items.